US equities
|
SPCX
$166.79
▲+4.93%
NVDA
$236.72
▲+1.18%
MU
$1,064.99
▼-0.92%
TSLA
$377.29
▲+1.81%
MSFT
$526.47
▲+1.73%
SNDK
$1,714.52
▼-0.32%
INTC
$117.24
▼-1.75%
META
$744.43
▲+2.25%
SPCX
$166.79
▲+4.93%
NVDA
$236.72
▲+1.18%
MU
$1,064.99
▼-0.92%
TSLA
$377.29
▲+1.81%
MSFT
$526.47
▲+1.73%
SNDK
$1,714.52
▼-0.32%
INTC
$117.24
▼-1.75%
META
$744.43
▲+2.25%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Junshi Biosciences
< Previous
1
2
Next >
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
June 25, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
June 18, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
June 11, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
April 24, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
April 07, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
March 29, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
February 01, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
January 17, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
January 09, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
January 02, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
December 01, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
November 22, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
October 27, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates
August 30, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer
July 19, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
July 11, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer
June 29, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer
May 23, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries
May 07, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma
April 27, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study
April 20, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
April 11, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients
April 11, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
March 31, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia
March 28, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies
February 27, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study
February 20, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
February 15, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Approval for Marketing of VV116 in China
January 30, 2023
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of NDA for VV116 in China
January 17, 2023
From
Junshi Biosciences
Via
GlobeNewswire
< Previous
1
2
Next >
